Recombinant SARS-CoV-2 S1 Subunit Protein, CendR Domain with mouse IgG Fc-tag

Protein-protein Interaction, Post-translational Modifications, ELISA, EIA, Western Blotting, Dot Blotting, Immunoprecipitation, Protein Array, etc.

C-terminal mouse IgG Fc-tag

-20°C

Recombinant SARS-CoV-2 S1 subunit protein, C-terminal CendR domain with a C-terminal mouse IgG Fc-tag, derived from the transfected human HEK293 cells.

S

Supplied as a 0.2 µm filtered solution in PBS (pH 7.4)

Spike protein, S Protein, S1 Subunit, CendR Domain

Lot specific (see the label on the vial), determined by BCA protein assay

Figure 1.Deglycosylation analysis of purified recombinant proteins. The same amount of purified proteins were untreated (Lane 2) or treated with protein deglycosylation enzymes under native (Lane 3) or reducing (Lane 4) conditions. Deglycosylation treatment resulted in a mobility shift of the protein to produce one reduced band at the expected size (ˆ¼45 kDa), thus indicating that the untreated recombinant protein (Lane 2) was glycosylated.Lane 1: Protein standard ladder (kDa)Lane 2: Untreated proteinLane 3: Treated protein with deglycosylation enzymes under native conditions.Lane 4: Treated protein with deglycosylation enzymes under denature conditions.Lane 5: Deglycosylation enzymes only without target proteins.